Intellia Therapeutics, Inc. financial data

Symbol
NTLA on Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
Location
40 Erie Street, Suite 130, Cambridge, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 918 % +13.1%
Return On Equity -45.9 % -10.2%
Return On Assets -37.9 % -12.9%
Operating Margin -983 % -23.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 96.5M shares +9.46%
Common Stock, Shares, Outstanding 96.3M shares +9.35%
Entity Public Float 3.57B USD -8.33%
Common Stock, Value, Issued 10K USD +11.1%
Weighted Average Number of Shares Outstanding, Basic 95.5M shares +8.81%
Weighted Average Number of Shares Outstanding, Diluted 95.5M shares +8.81%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 52.6M USD -1.63%
Research and Development Expense 450M USD +17.1%
General and Administrative Expense 120M USD +26%
Costs and Expenses 570M USD +18.9%
Operating Income (Loss) -517M USD -21.5%
Net Income (Loss) Attributable to Parent -486M USD -12.8%
Earnings Per Share, Basic -5.37 USD/shares 0%
Earnings Per Share, Diluted -5.37 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 172M USD -41.5%
Marketable Securities, Current 619M USD -3.14%
Accounts Receivable, after Allowance for Credit Loss, Current 36.4M USD +642%
Assets, Current 884M USD -8.26%
Property, Plant and Equipment, Net 32.1M USD +1.48%
Operating Lease, Right-of-Use Asset 110M USD -13.9%
Assets 1.26B USD -11.2%
Accounts Payable, Current 13.7M USD +98.7%
Employee-related Liabilities, Current 10.4M USD +3.23%
Accrued Liabilities, Current 43.3M USD -3.45%
Contract with Customer, Liability, Current 22.2M USD -37.2%
Liabilities, Current 97.9M USD -5.29%
Contract with Customer, Liability, Noncurrent 33.4M USD +141%
Operating Lease, Liability, Noncurrent 92.1M USD -16.1%
Other Liabilities, Noncurrent 10.8M USD
Liabilities 223M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax -947K USD +64.6%
Retained Earnings (Accumulated Deficit) -1.77B USD -37.9%
Stockholders' Equity Attributable to Parent 1.04B USD -13%
Liabilities and Equity 1.26B USD -11.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -121M USD -10.4%
Net Cash Provided by (Used in) Financing Activities 60M USD +2601%
Net Cash Provided by (Used in) Investing Activities 5.9M USD
Common Stock, Shares Authorized 240M shares +100%
Common Stock, Shares, Issued 96.3M shares +9.35%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -54.8M USD +76.1%
Deferred Tax Assets, Valuation Allowance 616M USD +35.5%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 648M USD +31.9%
Operating Lease, Liability 115M USD -11.8%
Payments to Acquire Property, Plant, and Equipment 2.51M USD -34.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -486M USD -14.3%
Lessee, Operating Lease, Liability, to be Paid 147M USD -14%
Property, Plant and Equipment, Gross 72.6M USD +18.8%
Operating Lease, Liability, Current 18.8M USD +14.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 25.9M USD +4.02%
Lessee, Operating Lease, Liability, to be Paid, Year One 26.4M USD +3.79%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 31.2M USD -21.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 25.1M USD -3.06%
Deferred Tax Assets, Operating Loss Carryforwards 259M USD +12.8%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 17.5M USD -30%
Operating Lease, Payments 25.5M USD +73.7%
Depreciation, Depletion and Amortization 2.51M USD +22.5%
Deferred Tax Assets, Net of Valuation Allowance 32.4M USD -11.9%
Share-based Payment Arrangement, Expense 141M USD +40.7%